Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY

Barchart · 1d ago

A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.